Urso is approved for the dissolution of existing small cholesterol gallstones, not for primary prevention. Lifestyle measures such as a balanced diet and maintaining a healthy weight remain the main strategies for reducing gallstone risk.
Many patients report a reduction in pruritus within 1-2 weeks of starting therapy, but individual response times can vary. Ongoing monitoring of bile-acid levels helps guide treatment duration.
Both strengths are white, round tablets, but the 300 mg tablets are typically larger in diameter. Imprint codes and packaging details are listed on the product label for verification.
Ursodeoxycholic acid can modestly lower serum cholesterol levels, particularly LDL cholesterol. This effect is generally considered beneficial but should be noted when interpreting lipid panels.
Aluminium- or magnesium-containing antacids do not significantly affect UDCA absorption. However, it is advisable to separate dosing by at least 2 hours to minimise any potential interaction.
While Urso can be absorbed without food, taking it with a meal improves tolerability and may enhance bioavailability. Consistency in timing (with or without food) helps maintain steady drug levels.
Urso tablets are permitted in both carry-on and checked luggage. Keep the medication in its original packaging with a clear label, and carry a copy of the prescription or a doctor’s note if required.
In patients with PBC, UDCA can slow disease progression, potentially delaying the need for transplantation. However, eligibility for transplant is determined by a comprehensive clinical assessment, not solely by medication use.
No robust data confirm a clinically significant interaction, but both agents affect liver metabolism. Patients should disclose all supplements to their clinician to ensure safe co-administration.
Urso, as a branded product, is generally priced higher than unbranded generic UDCA tablets. Pricing varies by pharmacy and NHS prescribing status; patients can discuss cost-effective options with their prescriber.
Urso is a branded medication that contains Ursodeoxycholic Acid as its active component. It is classified as a digestive-health agent and is available in pill form in strengths of 150 mg and 300 mg. In the United Kingdom, Urso is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). It is primarily prescribed for conditions involving impaired bile flow, such as primary biliary cholangitis and certain types of gallstones.
Ursodeoxycholic Acid (UDCA) is a naturally occurring bile acid that modifies the composition and flow of bile. Its key actions include:
These mechanisms collectively improve liver function and promote the clearance of abnormal bile constituents.
Urso is approved in the UK for the following indications:
In clinical practice, it may also be prescribed for other cholestatic liver disorders, but such use should follow specialist guidance.
Dosing must be individualized by a prescribing clinician based on body weight, disease severity, and treatment response.
This article provides educational information about Urso and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
